Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsErik FUNDER, Natascha HRUSCHKA, Susanne KAMMLER, Erich Koller, Brian Leonard, Souphalone LUANGSAY, Susanne MOHR, Tobias NILSSON, Søren OTTOSEN, Lykke PEDERSEN, Søren RASMUSSEN, Steffan SCHMIDT, Sabine SEWING, Daniel Turley, Johanna Marie WALTHER
Estimating the term…
Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.
An antisense oligonucleotide selected from the group of antisense oligonucleotides consisting of
A conjugate selected from the group of consisting of the conjugates shown in FIG. 1, FIG. 2, FIG. 3 and FIG. 4.
Dependencies are inferred from the claim text.